Brean Capital Reiterates Buy On Intellipharmaceutics Following FY3Q14 Results

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Intellipharmaceutics International (NASDAQ:IPCI) with a price target …

IPCI’s Novel Overdose Deterrence Technology Blows Us Away, Says Maxim

In a research report released September 5, Maxim Group analyst Jason Kolbert upgraded shares of IntelliPharmaCeutics (NASDAQ:IPCI) from Hold to Buy rating and raised his price target to $7.00 (from $3.

IntelliPharmaCeutics: We See No Reason To Be Long On Shares, Says Maxim

In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target.  The analyst commented: “IPCI reported the quarter last …

Maxim Group Downgrades Intellipharmaceutics To Hold, Lowers PT to $3

In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.